Shareholding disclosure

Cosmo Pharmaceuticals NV, Amsterdam

Declared position

3.005%

Threshold

Crossed upwards

Timeline

Published

17.08.2019

Transaction

15.08.2019

Transfer date

15.08.2019

Voting rights breakdown

Voting rights acquired3.005%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAJ8F000B0

Beneficial owner

Cosmo Pharmaceuticals NV, Amsterdam

Declared address

Cosmo Pharmaceuticals NV, Amsterdam

Kauf eigener Aktien

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Cosmo Pharmaceuticals NV, Amsterdam

Cosmo N.V.17.08.2019TAJ8F000B0

Disclosure summary

Cosmo Pharmaceuticals NV, Amsterdam disclosed a holding in Cosmo N.V. on the acquisition side, published by SIX Exchange Regulation on 17.08.2019, at 3.005% of voting rights. Notice category: Single shareholder.

Disclosed position

3.005%

Voting rights acquired

Voting rights acquired3.005%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Cosmo Pharmaceuticals NV, Amsterdam disclosed a holding in Cosmo N.V., published on 17.08.2019.

Publication date17.08.2019

Transaction date15.08.2019

Transfer date15.08.2019

Issuing companyCosmo N.V.

Beneficial ownerCosmo Pharmaceuticals NV, Amsterdam

Declared addressCosmo Pharmaceuticals NV, Amsterdam

CategorySingle shareholder

Voting rights acquired3.005%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAJ8F000B0

Conditions

Kauf eigener Aktien

Source: SIX Exchange Regulation · Publication date: 17.08.2019

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open